| Distribution | Full List | Categories |
| by Country | by Vaccine |
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries over 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| Israel |
62.8% 5,432,695 |
58.9% 5,097,642 |
0.1% | 0.2% |
0.2% 21k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Mongolia |
54.7% 1,792,657 |
19.9% 651,588 |
4.6% | 0.7% |
5.3% 173k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| United Kingdom |
54.1% 36,704,672 |
29.9% 20,287,403 |
1.8% | 3.6% |
5.4% 3,663k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bahrain |
49.8% 847,764 |
37.7% 642,187 |
2.5% | 3.1% |
5.6% 95k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Hungary |
48.8% 4,714,992 |
28.5% 2,749,235 |
3.8% | 2.3% |
6.1% 588k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| United States |
47.7% 157,827,208 |
37.4% 123,828,224 |
1.5% | 2.5% |
3.9% 12,813k |
|
| Johnson&Johnson, Moderna, Pfizer/BioNTech | ||||||
| Chile |
47.5% 9,077,086 |
39.2% 7,493,850 |
2.7% | 1.8% |
4.5% 860k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Canada |
46.0% 17,381,262 |
3.8% 1,424,641 |
6.3% | 0.4% |
6.8% 2,548k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Qatar |
41.9% 1,206,737 |
30.1% 866,617 |
2.8% | 5.2% |
7.9% 229k |
|
| Pfizer/BioNTech | ||||||
| Uruguay |
40.3% 1,401,145 |
27.3% 947,356 |
4.7% | 3.8% |
8.6% 297k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Finland |
38.5% 2,133,397 |
5.3% 291,296 |
3.4% | 1.5% |
4.8% 269k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Germany |
36.8% 30,838,708 |
11.1% 9,332,160 |
4.1% | 1.7% |
5.8% 4,825k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| United Arab Emirates |
35.2% 3,480,415 |
22.1% 2,187,849 |
3.1% 303k |
|||
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V | ||||||
| Belgium |
34.3% 3,975,576 |
12.1% 1,398,134 |
2.5% | 2.5% |
5.0% 576k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Serbia |
33.9% 2,304,204 |
26.0% 1,772,363 |
2.0% | 1.7% |
3.7% 250k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Austria |
33.5% 3,018,250 |
12.2% 1,101,135 |
3.4% | 1.2% |
4.5% 407k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Spain |
32.8% 15,320,846 |
15.4% 7,213,716 |
3.3% | 2.1% |
5.3% 2,482k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Singapore |
32.5% 1,900,000 |
22.2% 1,300,000 |
2.6% | 2.2% |
4.7% 276k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Lithuania |
32.2% 875,664 |
16.5% 450,304 |
2.9% | 2.2% |
5.1% 139k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Italy |
32.0% 19,334,589 |
14.6% 8,847,529 |
3.6% | 2.1% |
5.6% 3,365k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Portugal |
31.7% 3,233,193 |
13.7% 1,397,752 |
2.8% | 2.7% |
5.5% 563k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Sweden |
31.6% 3,194,265 |
9.7% 983,423 |
3.4% | 1.5% |
4.9% 498k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| France |
31.1% 20,317,788 |
13.8% 8,984,975 |
3.7% | 1.7% |
5.3% 3,477k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Poland |
30.8% 11,664,606 |
12.3% 4,642,010 |
3.3% | 2.4% |
5.5% 2,086k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Netherlands |
30.8% 5,269,132 |
10.0% 1,713,859 |
1.6% | 0.9% |
2.4% 405k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Estonia |
30.7% 407,204 |
13.5% 179,044 |
2.4% | 1.3% |
3.7% 49k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Czechia |
29.2% 3,128,196 |
10.4% 1,112,078 |
4.1% | 0.4% |
4.4% 475k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Norway |
29.1% 1,576,524 |
10.9% 588,603 |
1.6% | 2.0% |
3.6% 195k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Denmark |
28.7% 1,662,452 |
18.0% 1,040,386 |
2.7% | 3.0% |
5.7% 331k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Ireland |
28.5% 1,408,655 |
10.4% 514,808 |
4.2% | 1.2% |
5.4% 267k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Greece |
27.2% 2,836,972 |
15.6% 1,624,604 |
3.2% | 3.3% |
6.2% 645k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Slovenia |
26.9% 560,106 |
14.2% 294,282 |
3.4% | 1.8% |
5.2% 108k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Slovakia |
26.3% 1,437,945 |
12.5% 682,858 |
2.7% | 1.5% |
4.2% 229k |
|
| Pfizer/BioNTech | ||||||
| Croatia |
25.6% 1,052,032 |
7.7% 317,937 |
3.8% | 1.4% |
5.2% 216k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Dominican Republic |
21.2% 2,299,179 |
7.6% 820,641 |
7.0% | 0.1% |
7.1% 766k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Latvia |
21.0% 395,948 |
6.4% 121,684 |
3.4% | 1.9% |
5.2% 97k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Romania |
20.6% 3,963,176 |
15.1% 2,902,964 |
1.5% | 2.5% |
3.8% 739k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Kuwait |
19.2% 822,000 |
0.9% 38,000 |
6.2% 266k |
|||
| Pfizer/BioNTech | ||||||
| Argentina |
17.8% 8,050,709 |
4.3% 1,952,121 |
0.7% | 1.2% |
2.0% 880k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Turkey |
17.8% 14,986,982 |
13.0% 10,963,952 |
0.4% | 0.7% |
1.1% 933k |
|
| Pfizer/BioNTech, Sinovac | ||||||
| Morocco |
17.5% 6,458,947 |
12.3% 4,542,426 |
2.0% | 0.4% |
2.4% 870k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Brazil |
17.1% 36,355,939 |
8.1% 17,268,389 |
2.0% | 0.9% |
2.9% 6,259k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Mauritius |
16.7% 212,182 |
0.7% 8,464 |
1.1% | 0.1% |
1.2% 15k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| El Salvador |
16.0% 1,036,121 |
5.7% 366,265 |
0.8% | 2.3% |
3.1% 201k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Albania |
15.9% 456,980 |
7.8% 223,103 |
15.7% | 7.7% |
2.3% 67k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Panama |
13.1% 565,026 |
6.5% 279,052 |
1.1% | 0.5% |
1.6% 68k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Costa Rica |
12.9% 657,301 |
8.6% 436,630 |
1.0% | 1.8% |
2.8% 144k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cambodia |
12.6% 2,100,151 |
7.4% 1,232,928 |
1.6% | 0.7% |
2.3% 390k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Mexico |
12.1% 15,544,106 |
8.3% 10,652,500 |
0.9% | 0.8% |
1.4% 1,751k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| India |
10.4% 143,090,218 |
3.0% 40,726,986 |
0.6% | 0.3% |
0.9% 12,718k |
|
| Covaxin, Oxford/AstraZeneca | ||||||
| Bulgaria |
10.2% 709,006 |
6.1% 425,971 |
0.8% | 1.6% |
2.5% 171k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Azerbaijan |
10.2% 1,030,831 |
7.5% 764,218 |
0.2% | 0.8% |
1.1% 108k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Russia |
9.8% 14,361,832 |
6.7% 9,725,703 |
0.8% | 0.8% |
1.6% 2,301k |
|
| EpiVacCorona, Sputnik V | ||||||
| Kazakhstan |
9.8% 1,844,938 |
4.0% 759,059 |
0.8% | 0.9% |
1.7% 312k |
|
| QazVac, Sinopharm/HayatVax, Sputnik V | ||||||
| WORLD |
9.1% 711,418,646 |
4.6% 359,512,360 |
0.6% | 0.5% |
2.2% 172,646k |
|
| Colombia |
9.0% 4,601,785 |
5.6% 2,857,547 |
1.1% | 0.9% |
2.1% 1,060k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| North Macedonia |
8.5% 176,909 |
1.3% 26,415 |
3.8% | 1.3% |
5.1% 106k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Jordan |
7.9% 805,020 |
2.8% 286,028 |
0.9% | 0.7% |
1.6% 168k |
|
| Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| South Korea |
7.3% 3,745,934 |
2.0% 1,039,642 |
0.1% | 0.9% |
1.0% 509k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Nepal |
7.2% 2,113,080 |
2.5% 728,296 |
0.1% | 1.0% |
1.0% 302k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Bolivia |
7.0% 821,241 |
2.5% 285,484 |
0.7% | 0.1% |
0.8% 96k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Ecuador |
6.7% 1,179,062 |
2.0% 345,662 |
0.9% | 0.4% |
1.3% 235k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Laos |
6.5% 474,983 |
1.2% 88,483 |
2.0% | 0.2% |
2.2% 156k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Sri Lanka |
6.1% 1,300,558 |
1.3% 269,512 |
1.7% | 0.3% |
2.0% 440k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Lebanon |
5.9% 399,742 |
3.0% 207,252 |
0.7% | 0.2% |
0.9% 62k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| New Zealand |
5.6% 268,787 |
2.5% 120,090 |
1.0% | 0.7% |
1.7% 82k |
|
| Pfizer/BioNTech | ||||||
| Peru |
5.3% 1,761,504 |
2.4% 787,444 |
0.9% | 0.2% |
1.1% 371k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Palestine |
5.3% 271,607 |
3.8% 195,207 |
0.2% | 0.1% |
0.2% 10k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Tunisia |
5.3% 628,107 |
1.6% 195,507 |
0.8% | 0.3% |
1.0% 121k |
|
| Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Moldova |
5.2% 209,881 |
0.8% 33,065 |
1.2% | 0.2% |
1.4% 58k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Indonesia |
5.1% 13,828,102 |
3.3% 9,093,965 |
0.2% | 0.1% |
0.3% 813k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Oman |
4.9% 253,000 |
1.4% 73,269 |
0.2% |
0.2% 11k |
||
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Equatorial Guinea |
4.6% 64,646 |
0.8% 10,872 |
1.7% | 0.2% |
1.9% 26k |
|
| Sinopharm/Beijing | ||||||
| Jamaica |
4.6% 135,473 |
3.1% |
3.1% 92k |
|||
| Oxford/AstraZeneca | ||||||
| Trinidad and Tobago |
4.3% 60,671 |
0.1% 1,179 |
0.0% | 0.0% |
0.0% 1k |
|
| Oxford/AstraZeneca | ||||||
| Zimbabwe |
4.0% 591,808 |
1.5% 222,450 |
0.4% | 0.4% |
0.8% 124k |
|
| Sinopharm/Beijing | ||||||
| Malaysia |
3.8% 1,219,234 |
2.3% 756,851 |
0.3% | 0.2% |
0.6% 183k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Japan |
3.7% 4,725,079 |
1.5% 1,966,189 |
1.0% | 0.6% |
1.5% 1,957k |
|
| Pfizer/BioNTech | ||||||
| Bangladesh |
3.5% 5,819,912 |
2.3% 3,757,023 |
0.0% | 0.1% |
0.1% 228k |
|
| Oxford/AstraZeneca | ||||||
| Togo |
3.3% 276,000 |
0.3% |
0.3% 27k |
|||
| Oxford/AstraZeneca | ||||||
| Uzbekistan |
3.3% 1,095,112 |
0.6% 190,103 |
0.7% | 0.3% |
0.9% 320k |
|
| Oxford/AstraZeneca, RBD-Dimer, Sputnik V | ||||||
| Belarus |
3.2% 300,000 |
1.6% 150,000 |
0.3% | 0.3% |
0.6% 61k |
|
| Sputnik V | ||||||
| Myanmar |
3.1% 1,689,551 |
1.6% 854,211 |
0.2% | 0.6% |
0.9% 473k |
|
| Oxford/AstraZeneca | ||||||
| Ghana |
2.7% 852,047 |
0.0% |
0.0% 3k |
|||
| Oxford/AstraZeneca | ||||||
| Rwanda |
2.7% 350,400 |
0.0% |
0.0% 1k |
|||
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Senegal |
2.6% 431,916 |
0.1% |
0.1% 10k |
|||
| Sinopharm/Beijing | ||||||
| Bosnia and Herzegovina |
2.5% 83,260 |
0.7% 23,204 |
0.8% | 0.3% |
1.1% 36k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Nicaragua |
2.5% 166,350 |
0.2% |
0.2% 17k |
|||
| Oxford/AstraZeneca, Sputnik V | ||||||
| Kosovo |
2.4% 46,097 |
0.4% |
0.4% 7k |
|||
| Oxford/AstraZeneca | ||||||
| Timor |
2.3% 30,599 |
0.8% |
0.8% 10k |
|||
| Oxford/AstraZeneca | ||||||
| Botswana |
2.3% 53,375 |
0.2% |
0.2% 3k |
|||
| Oxford/AstraZeneca | ||||||
| Georgia |
2.2% 89,260 |
0.4% 14,643 |
0.7% | 0.1% |
0.8% 31k |
|
| Oxford/AstraZeneca | ||||||
| Paraguay |
2.2% 159,422 |
0.2% 15,705 |
0.4% | 0.0% |
0.5% 35k |
|
| Sputnik V | ||||||
| Thailand |
2.2% 1,521,034 |
1.2% 819,961 |
0.2% | 0.4% |
0.6% 443k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Ukraine |
2.2% 948,330 |
0.1% 27,454 |
0.2% | 0.1% |
0.2% 110k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Philippines |
2.0% 2,245,397 |
0.6% 675,799 |
0.3% | 0.2% |
0.5% 526k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Namibia |
2.0% 50,222 |
0.1% 2,941 |
0.5% | 0.0% |
0.5% 13k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Angola |
1.8% 586,377 |
0.1% 40,195 |
0.2% | 0.1% |
0.2% 63k |
|
| Oxford/AstraZeneca | ||||||
| Iran |
1.8% 1,475,436 |
0.3% 292,134 |
0.5% | 0.1% |
0.6% 490k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Malawi |
1.8% 334,363 |
0.1% |
0.1% 14k |
|||
| Oxford/AstraZeneca | ||||||
| Kenya |
1.7% 933,436 |
0.1% |
0.1% 35k |
|||
| Oxford/AstraZeneca, Sputnik V | ||||||
| Guatemala |
1.5% 277,380 |
0.0% 2,522 |
0.4% | 0.0% |
0.4% 64k |
|
| Moderna, Oxford/AstraZeneca | ||||||
| Libya |
1.5% 106,559 |
0.5% |
0.5% 32k |
|||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| Pakistan |
1.3% 2,931,064 |
0.4% 964,227 |
0.4% | 0.4% |
0.2% 516k |
|
| CanSino, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Cote d'Ivoire |
1.3% 340,049 |
0.3% |
0.3% 73k |
|||
| Oxford/AstraZeneca | ||||||
| Afghanistan |
1.1% 448,878 |
0.1% 55,624 |
0.2% | 0.1% |
0.2% 97k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Iraq |
1.1% 453,361 |
0.2% |
0.2% 60k |
|||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Egypt |
1.1% 1,133,956 |
0.2% 238,020 |
0.1% | 0.1% |
0.2% 217k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Guinea |
1.1% 143,908 |
0.5% 60,809 |
0.3% | 0.1% |
0.4% 54k |
|
| Sputnik V | ||||||
| Gambia |
1.0% 24,659 |
0.1% |
0.1% 2k |
|||
| Oxford/AstraZeneca | ||||||
| Vietnam |
1.0% 954,520 |
0.0% 22,512 |
0.2% | 0.0% |
0.2% 214k |
|
| Oxford/AstraZeneca | ||||||
| Mozambique |
0.9% 296,983 |
0.2% 59,012 |
0.1% | 0.0% |
0.1% 42k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Uganda |
0.9% 430,301 |
0.1% |
0.1% 34k |
|||
| Oxford/AstraZeneca | ||||||
| Venezuela |
0.9% 250,000 |
0.4% |
0.4% 106k |
|||
| Sputnik V | ||||||
| Nigeria |
0.9% 1,823,095 |
0.1% |
0.1% 126k |
|||
| Oxford/AstraZeneca | ||||||
| South Africa |
0.8% 478,733 |
0.8% 478,733 |
0.1% | 0.1% |
0.1% 84k |
|
| Johnson&Johnson | ||||||
| Somalia |
0.8% 123,570 |
0.0% |
0.0% 3k |
|||
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Lesotho |
0.8% 16,000 |
|||||
| Oxford/AstraZeneca | ||||||
| Tajikistan |
0.7% 70,517 |
|||||
| Oxford/AstraZeneca | ||||||
| Sierra Leone |
0.7% 58,250 |
0.1% 6,716 |
0.0% | 0.0% |
0.1% 4k |
|
| Oxford/AstraZeneca | ||||||
| Liberia |
0.7% 36,404 |
|||||
| Oxford/AstraZeneca | ||||||
| Armenia |
0.6% 19,249 |
0.3% |
0.3% 9k |
|||
| Oxford/AstraZeneca, Sinovac, Sputnik V | ||||||
| Australia |
0.6% 159,294 |
1.7% 437k |
||||
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Zambia |
0.6% 114,767 |
0.2% |
0.2% 33k |
|||
| Oxford/AstraZeneca | ||||||
| Cuba |
0.6% 70,000 |
|||||
| Abdala | ||||||
| Kyrgyzstan |
0.6% 37,117 |
0.1% 6,010 |
0.1% | 0.0% |
0.1% 8k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Honduras |
0.6% 55,000 |
0.0% 2,639 |
0.0% | 0.0% |
0.1% 5k |
|
| Moderna, Oxford/AstraZeneca | ||||||
| Sudan |
0.5% 204,838 |
0.2% 85,662 |
0.1% | 0.1% |
0.2% 66k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Congo |
0.4% 22,531 |
0.3% 15,620 |
0.0% | 0.1% |
0.1% 6k |
|
| Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Eswatini |
0.4% 35,227 |
0.0% |
0.0% 0k |
|||
| Oxford/AstraZeneca | ||||||
| Gabon |
0.4% 8,515 |
0.2% 3,849 |
0.0% | 0.1% |
0.1% 2k |
|
| Sinopharm/Beijing | ||||||
| Mali |
0.3% 71,216 |
0.1% 13,064 |
0.0% | 0.0% |
0.1% 13k |
|
| Oxford/AstraZeneca | ||||||
| Mauritania |
0.3% 15,661 |
0.1% |
0.1% 3k |
|||
| Sinopharm/Beijing | ||||||
| Guinea-Bissau |
0.3% 5,889 |
|||||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Niger |
0.3% 68,158 |
0.0% 5,948 |
0.1% | 0.0% |
0.1% 20k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Cameroon |
0.2% 43,488 |
0.0% 903 |
0.1% | 0.0% |
0.1% 18k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Taiwan |
0.1% 32,389 |
0.5% 112k |
||||
| Oxford/AstraZeneca | ||||||
| Benin |
0.1% 10,683 |
|||||
| Oxford/AstraZeneca, Sinovac | ||||||
| Yemen |
0.1% 18,555 |
|||||
| Oxford/AstraZeneca | ||||||
| South Sudan |
0.1% 5,459 |
0.0% |
0.0% 1k |
|||
| Oxford/AstraZeneca | ||||||
| Papua New Guinea |
0.0% 3,000 |
|||||
| Oxford/AstraZeneca | ||||||
| Democratic Republic of Congo |
0.0% 8,446 |
0.0% |
0.0% 3k |
|||
| Oxford/AstraZeneca | ||||||
| Central African Republic |
0.0% 667 |
|||||
| Covaxin, Oxford/AstraZeneca | ||||||
| Syria |
0.0% 2,500 |
|||||
| Sputnik V | ||||||
| Saudi Arabia |
*32.8% 11,419,299 |
2.9% 1,020k |
||||
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| China |
*29.3% 421,991,000 |
6.2% 89,027k |
||||
| Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac | ||||||
| Ethiopia |
*1.3% 1,454,503 |
0.1% 164k |
||||
| Oxford/AstraZeneca | ||||||
| Algeria |
*0.2% 75,000 |
0.1% 26k |
||||
| Sputnik V | ||||||
| Madagascar |
0.0% 609 |
|||||
| Oxford/AstraZeneca | ||||||
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries below 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| Gibraltar |
115.5% 38,905 |
105.5% 35,556 |
1.3% | 1.6% |
2.9% 1k |
|
| Pfizer/BioNTech | ||||||
| Falkland Islands |
75.6% 2,632 |
51.0% 1,775 |
0.8% | 1.7% |
2.4% 0k |
|
| Oxford/AstraZeneca | ||||||
| Isle of Man |
71.8% 61,081 |
18.7% 15,896 |
3.5% | 0.1% |
3.6% 3k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Seychelles |
71.1% 69,915 |
62.7% 61,631 |
1.0% | 0.9% |
1.9% 2k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| San Marino |
64.4% 21,862 |
49.8% 16,904 |
1.4% | 12.6% |
14.0% 5k |
|
| Pfizer/BioNTech, Sputnik V | ||||||
| Malta |
64.4% 284,395 |
32.5% 143,487 |
5.8% | 5.1% |
10.1% 44k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Bhutan |
62.5% 482,128 |
0.1% |
0.1% 1k |
|||
| Oxford/AstraZeneca | ||||||
| Cayman Islands |
60.5% 39,792 |
51.6% 33,921 |
3.5% | 2.5% |
6.0% 4k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Anguilla |
58.7% 8,811 |
29.5% 4,424 |
5.0% | 6.8% |
11.8% 2k |
|
| Oxford/AstraZeneca | ||||||
| Bermuda |
56.2% 34,966 |
46.6% 29,028 |
2.3% | 4.3% |
6.5% 4k |
|
| Pfizer/BioNTech | ||||||
| Maldives |
56.1% 303,336 |
26.9% 145,372 |
0.4% | 2.1% |
2.5% 13k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Jersey |
55.1% 55,684 |
38.5% 38,890 |
1.3% | 1.6% |
2.8% 3k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Aruba |
54.3% 57,936 |
31.0% 33,070 |
1.8% | 7.0% |
8.8% 9k |
|
| Pfizer/BioNTech | ||||||
| Guernsey |
49.2% 32,969 |
20.3% 13,618 |
4.0% 3k |
|||
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Curacao |
48.7% 79,954 |
27.8% 45,679 |
1.6% | 7.9% |
9.5% 16k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Iceland |
43.2% 147,592 |
19.0% 65,011 |
2.6% | 3.3% |
5.7% 19k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Faeroe Islands |
39.2% 19,153 |
16.0% 7,824 |
4.6% | 2.5% |
7.1% 3k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Turks and Caicos Islands |
38.8% 15,039 |
25.8% 10,000 |
1.0% |
1.0% 0k |
||
| Pfizer/BioNTech | ||||||
| Cyprus |
38.2% 334,258 |
13.1% 114,476 |
5.7% | 3.1% |
8.8% 77k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Monaco |
35.5% 13,934 |
30.6% 12,003 |
1.6% | 0.5% |
2.1% 1k |
|
| Pfizer/BioNTech | ||||||
| Andorra |
34.9% 26,931 |
6.1% 4,702 |
3.6% |
3.6% 3k |
||
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Sint Maarten (Dutch part) |
34.2% 14,678 |
23.2% 9,956 |
||||
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Antigua and Barbuda |
31.9% 31,262 |
0.6% |
0.6% 1k |
|||
| Oxford/AstraZeneca | ||||||
| Luxembourg |
31.9% 199,581 |
13.6% 85,332 |
3.9% | 3.1% |
7.0% 44k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Liechtenstein |
27.6% 10,518 |
13.8% 5,247 |
2.3% | 2.8% |
5.1% 2k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Dominica |
26.5% 19,099 |
19.4% 13,938 |
0.4% | 3.2% |
3.6% 3k |
|
| Oxford/AstraZeneca | ||||||
| Barbados |
26.4% 75,956 |
15.3% 43,867 |
0.2% | 3.9% |
4.0% 12k |
|
| Oxford/AstraZeneca | ||||||
| Saint Kitts and Nevis |
26.0% 13,821 |
3.3% 1,746 |
1.4% | 2.7% |
4.1% 2k |
|
| Oxford/AstraZeneca | ||||||
| Montserrat |
25.9% 1,293 |
12.3% 616 |
3.0% |
3.2% 0k |
||
| Oxford/AstraZeneca | ||||||
| Bonaire Sint Eustatius and Saba |
21.8% 5,726 |
6.3% 1,665 |
||||
| Moderna, Pfizer/BioNTech | ||||||
| Greenland |
19.2% 10,921 |
11.3% 6,403 |
2.8% | 1.7% |
4.5% 3k |
|
| Pfizer/BioNTech | ||||||
| Guyana |
19.2% 150,694 |
0.4% 2,800 |
2.4% |
2.4% 19k |
||
| Oxford/AstraZeneca, Sputnik V | ||||||
| Montenegro |
17.2% 107,881 |
5.4% 33,927 |
3.9% | 0.4% |
4.3% 27k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| New Caledonia |
15.4% 43,941 |
11.1% 31,639 |
0.9% | 1.8% |
2.7% 8k |
|
| Oxford/AstraZeneca | ||||||
| Belize |
13.3% 52,753 |
1.3% |
1.3% 5k |
|||
| Oxford/AstraZeneca | ||||||
| Grenada |
12.2% 13,744 |
5.1% 5,775 |
0.6% | 1.6% |
2.1% 2k |
|
| Oxford/AstraZeneca | ||||||
| Saint Lucia |
11.0% 20,247 |
0.6% 1k |
||||
| Oxford/AstraZeneca | ||||||
| Fiji |
10.4% 93,000 |
1.4% |
1.4% 12k |
|||
| Oxford/AstraZeneca | ||||||
| Bahamas |
9.1% 36,000 |
1.5% |
1.5% 6k |
|||
| Oxford/AstraZeneca | ||||||
| Suriname |
8.9% 52,109 |
0.3% 2,053 |
0.9% | 0.2% |
1.2% 7k |
|
| Oxford/AstraZeneca | ||||||
| Samoa |
6.0% 11,950 |
2.3% |
2.3% 5k |
|||
| Oxford/AstraZeneca | ||||||
| Comoros |
5.0% 43,140 |
0.1% 588 |
1.1% | 0.0% |
1.2% 10k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Sao Tome and Principe |
4.4% 9,724 |
2.6% |
2.6% 6k |
|||
| Oxford/AstraZeneca | ||||||
| Brunei |
3.4% 15,043 |
0.2% 862 |
0.6% | 0.1% |
0.7% 3k |
|
| Oxford/AstraZeneca | ||||||
| Cape Verde |
3.3% 18,650 |
0.5% 2,668 |
0.4% | 0.1% |
0.5% 3k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Solomon Islands |
1.4% 9,340 |
0.5% 3,479 |
0.7% |
0.2% 2k |
||
| Oxford/AstraZeneca | ||||||
| Djibouti |
1.3% 12,547 |
0.1% 495 |
0.2% | 0.0% |
0.2% 2k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Saint Vincent and the Grenadines |
*15.1% 16,726 |
1.3% 1k |
||||
| Oxford/AstraZeneca | ||||||